Mefloquine versus 3-day oral quinine-clindamycin in uncomplicated imported falciparum malaria

Travel Medicine and Infectious Disease

Volumn 5, Issue 5, 2007, Pages 306-309

  Ranque, Stéphane ^a   Parola, Philippe ^a   Adehossi, Eric ^b   Brouqui, Philippe ^b   Delmont, Jean ^b  

^a AIX MARSEILLE UNIVERSITY   (France)

^b HÔPITAL NORD   (France)

Author keywords

Falciparum; Imported; Malaria; Randomised trial; Uncomplicated

Indexed keywords

CLINDAMYCIN; DALACINE; MEFLOQUINE; QUINIMAX; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACUTE PSYCHOSIS; ADULT; ANOREXIA; ANXIETY; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; COLITIS; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DELUSION; DIGESTIVE SYSTEM DISEASE; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ESOPHAGITIS; FEMALE; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HUMAN; HYPOACUSIS; IMPORT DISEASE; INSOMNIA; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; MEMORY DISORDER; MENTAL DISEASE; MOOD DISORDER; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; NIGHTMARE; OPEN STUDY; PARESTHESIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; PURPURA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TINNITUS; TREATMENT DURATION; VERTIGO; VISUAL DISORDER; VOMITING;

ADMINISTRATION, ORAL; ADULT; ANTIMALARIALS; CLINDAMYCIN; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALARIA, FALCIPARUM; MALE; MEFLOQUINE; MIDDLE AGED; QUININE; TRAVEL;

EID: 34548537587     PISSN: 14778939     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tmaid.2007.07.001     Document Type: Article

References (15)

1. Anonymous. Dealing with and preventing imported malaria due to Plasmodium falciparum. Méd Mal Infect 29 6 (1999) 375-379
2. Parola P., Ranque S., Badiaga S., et al. Controlled trial of 3-day quinine-clindamycin treatment versus 7-day quinine treatment for adult travelers with uncomplicated falciparum malaria imported from the tropics. Antimicrob Agents Chemother 45 3 (2001) 932-935
3. Adehossi E., Parola P., Foucault C., et al. Three-day quinine-clindamycin treatment of uncomplicated falciparum malaria imported from the tropics. Antimicrob Agents Chemother 47 3 (2003) 1173
4. Ranque S., Marchou B., Malvy D., et al. Treatment of imported malaria in adults: a multicentre study in France. QJM Int J Med 98 10 (2005) 737-743
5. World Health Organization. Severe falciparum malaria. Trans R Soc Trop Med Hyg 94 Suppl 1 (2000) 1-90
6. ter Kuile F.O., Nosten F., Luxemburger C., et al. Mefloquine treatment of acute falciparum malaria: a prospective study of non-serious adverse effects in 3673 patients. Bull World Health Organ 73 5 (1995) 631-642
7. Rendi-Wagner P., Noedl H., Wernsdorfer W.H., Wiedermann G., Mikolasek A., and Kollaritsch H. Unexpected frequency, duration and spectrum of adverse events after therapeutic dose of mefloquine in healthy adults. Acta Trop 81 2 (2002) 167-173
8. van Riemsdijk M.M., Sturkenboom M.C., Ditters J.M., et al. Low body mass index is associated with an increased risk of neuropsychiatric adverse events and concentration impairment in women on mefloquine. Br J Clin Pharmacol 57 4 (2004) 506-512
9. Croft A.M., Whitehouse D.P., Cook G.C., and Beer M.D. Safety evaluation of the drugs available to prevent malaria. Expert Opin Drug Saf 1 1 (2002) 19-27
10. Ollivier L., Tifratene K., Josse R., Keundjian A., and Boutin J.P. The relationship between body weight and tolerance to mefloquine prophylaxis in non-immune adults: results of a questionnaire-based study. Ann Trop Med Parasitol 98 6 (2004) 639-641
11. van Riemsdijk M.M., Sturkenboom M.C., Pepplinkhuizen L., and Stricker B.H. Mefloquine increases the risk of serious psychiatric events during travel abroad: a nationwide case-control study in the Netherlands. J Clin Psychiatry 66 2 (2005) 199-204
12. Aarnoudse A.L., van Schaik R.H., Dieleman J., et al. MDR1 gene polymorphisms are associated with neuropsychiatric adverse effects of mefloquine. Clin Pharmacol Ther 80 4 (2006) 367-374
13. Lell B., and Kremsner P.G. Clindamycin as an antimalarial drug: review of clinical trials. Antimicrob Agents Chemother 46 8 (2002) 2315-2320
14. Looareesuwan S., Chulay J.D., Canfield C.J., and Hutchinson D.B. Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Malarone Clinical Trials Study Group. Am J Trop Med Hyg 60 4 (1999) 533-541
15. Hitani A., Nakamura T., Ohtomo H., Nawa Y., and Kimura M. Efficacy and safety of atovaquone-proguanil compared with mefloquine in the treatment of nonimmune patients with uncomplicated P. falciparum malaria in Japan. J Infect Chemother 12 5 (2006) 277-282